Using an active, HA1 epitope-tagged form of the murine erythropoietin (EPO) receptor and via direct coimmunoprecipitation, the p85 regulatory subunit of phosphatidyl inositol-3 kinase (p85/P13-K) is shown to associate with the EPO receptor in transfected FDC-P1 cell lines. Coimmunoprecipitation of p85 with epitope-tagged EPO receptors was observed initially in FDC-HER cells labeled metabolically with [32P]orthophosphate, and association of these factors was confirmed by Western analyses of receptor immunoprecipitates using p85 antiserum. Interestingly, this association occurred in the absence of ligand, and exposure of FDC-HER cells to EPO did not detectably affect levels of receptor-associated p85 or overall levels of p85 phosphorylation. However, EPO was observed to stimu-URING RED BLOOD CELL development, pro-D erythroblasts in marrow, spleen, and fetal liver (colony forming units-erythroid [CFU-e]) require exposure to the glycoprotein hormone, erythropoietin (EPO), for survival, proliferation, and terminal differentiation.'-' Insight into mechanisms involved in proliferative signalling has been provided, in part, through the recent cloning and analysis of the murine and human EPO receptors.495 Linked pattern sequence analyses originally of receptors for growth hormone, prolactin, interleukin-6 (IL-6), and IL-26 showed that the EPO receptor is related structurally to these, and an expanding superfamily of cytokine receptors (eg, receptors for IL-3, IL-4, IL-5, IL-7, granulocyte-macrophage colonystimulating factor [GM-CSF], granulocyte-CSF [G-CSF], leukocyte-inhibitory factor [LIF], and ciliary neurotrophic factor [CNTF]).7 Conserved structure exists primarily within extracellular domains and includes four codistributed cysteine residues, a membrane proximal WSXWS motif, and paired sevenfold p-strand predicted ligand-binding domains. Limited homology within membrane-proximal cytosolic regions also has been recognized among the recep-
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tors for EPO, IL-6 (gpl30), IL-2 (p-receptor), IL-3, G-CSF, IL-7, and IL-4 and is restricted to conserved 8-to 12-amino acid essential box-1 and box-2 subdomains and intervening residue^.^^^ Within the EPO receptor, a subdomain immediately distal to the box 2 domain also has been shown to be essential for mitogenic signalling.10%" Functional subdomains have been delineated largely through studies of reconstituted mitogenic activity of mutated EPO receptor forms in transfected myeloid and lymphoid cell lines." These studies also show that a delimited membrane-proximal 90-amino acid cytosolic receptor domain (including the above box motifs) mediates EPO-induced pr~liferation,'~,~' whereas mitogenic signalling is modulated negatively by a distal carboxyl terminal With regard to mechanisms of proliferative signalling, early studies using isolated proerythroblasts have associated EPO action with increases in intracellular calcium, cyclic AMP, and arachidonic acid." However, little progress has been made in identifying direct targets in these pathways, and no recognizable catalytic domains are encoded within the cloned EPO receptor. More recently, EPO has been shown to rapidly activate protein tyrosine phosphorylation,I5 and EPO-induced tyrosine phosphorylation of raf-1,16 p120-GAP,I7 the EPO receptor per se," and additional cellular protein^'^.*^ has been demonstrated. The latter proteins include a molecular weight (Mr) 97,000/ 100,000 cytosolic factor,"*' which also is tyrosine phosphorylated in response to IL-3 and GM-CSF," as well as an Mr 130,000 potential protein tyrosine kinase (PTK) that associates with EPO-receptor complexes." Very recent studies by Witthuhn et al'' indicate that this Mr 130,000 PTK corresponds to JAK2, a member of the Janus family of PTKsZ4 that is shown in vitro to associate with the EPO receptor and to be activated by EPO. Thus, the above work aligns the EPO receptor mechanistically with growth factor receptors that directly encode ligand- present study, the apparent overlap in mechanisms of proliferative signal transduction for these receptors versus the EPO receptor is extended through the observed constitutive association between an epitope-tagged form of the murine EPO receptor with the regulatory subunit of a second kinase that is known to associate with at least certain PTK-encoding receptors, ie, phosphatidylinositol-3 kinase (P13-K).27,28 Using recombinant factors expressed in insect SF9 cells, the essential extended box-2 cytosolic subdomain of the EPO receptorlo*'' is also delineated as a candidate site for p85 binding.
MATERIALS AND METHODS
Cell lines and mitogenic assays. Murine myeloid IL-3/GM-CSF-dependent FDC-P 1 cells;9 FDC-ER cells," and FDC-HER cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, mol/L 2-mercaptoethanol, and 3% conditioned medium from WEHI-3B cells3' Proliferation assays were performed in 96-well plates (2 X lo4 cells; 0.1 mL) using purified recombinant human EPO (Amgen Biologicals, Thousand Oaks, CA). Cells were labeled for 2 hours at 48 hours of culture with ['Hlthymidine (10 pCi/mL).
Construction of epitope-tagged and mutated EPO receptor forms. In part to improve immunoprecipitation of EPO receptors from transfected cell lines, an epitope (YDVPDYAS) derived from influenza virus hemagglutinin" was used to tag the murine EPO receptor at the amino terminus. A cDNA encoding this epitope (and a signal peptide for secretion) was prepared by polymerase chain reaction (PCR) from an epitope-tagged form of EPO', using the primers S'-ACGGGTACCATGGGGGTGCACGAATG-3' and 5'-ATGGTCGACGCTGGCGTAGTCTGGGA-3'. This amplified fragment was cloned into Kpn I and Sal I sites of pBluescript-IIKS+ (Stratagene, La Jolla, CA). PCR primers (5'-TCGGTCGACGCA-CCTTCACCCAGCCT-3' and 5'-TCCCCAGCCTGAGTCACT-GCCCAGCG-3') were then used to amplify the amino terminus (A1-G3,') of murine EPO receptor cDNA. This amplified fragment was cloned into the above construct at Sal I and BamHI sites, yielding a construct encoding the HA1 epitope, two intervening residues (V and D), and the N-terminus ofthe mature receptor. A full-length construct (pBHER) was completed by subcloning the BamHI to Not I fragment of the EPO receptor into the above construct, and this tagged EPO receptor cDNA was cloned into 5' Kpn I and 3'Not I sites of a modified pXM4 expression vector (pXM-HER). Truncated epitope-tagged EPO receptor (HER) forms were constructed by inserting a 14-bp Xba I stop linker (Pharmacia, Piscataway, NJ) into the blunt-ended Bgl I1 site of pXM-HER (HER-K256) and inserting a cassette with stop codons in each reading frame (5'-AGC-TAGTCTAGACTAGC-3' and 5'-GGCCGCTAGTCTAGACT-3') at Hind111 and Not I sites of pXM-HER (HER-E374). A receptor form with an in-frame deletion of the box 2 cytosolic domain (HERAB X 2) was constructed by ligating the BamHI and Apa I sites of the above construct using the oligo 5'-GATCGGCC-3' (resulting in the insertion of a single arginine residue). All constructs were confirmed by restriction analyses and DNA sequencing.
HAI-tagged EPO receptor cDNAs (42 pg) were cotransfected with a G4 18-resistance plasmid (pM5-neo, 8 pg) into FDC-PI cells ( IO7 cells/mL in phosphate-buffered saline [PBS]) by high-voltage electroporation (562 V/cm, 950 p F geneZAPPER, IBI, New Haven, CT). Transfected cells were selected in G418 at 1 mg/mL (Geneticin; GIBCO BRL, Grand Island, NY) and, subsequently, in medium lacking conditioned medium from WEHI-3 cells and containing EPO (5 U/mL). Sublines were established by dilutional cloning.
Gene transfer.
Receptor immunoprecipitation, metabolic labeling, and Western blotting. Exponentially growing FDC-P 1 -derived cell lines typically were washed three times in DMEM and were starved in DMEM plus 1% fetal calfserum for 12 hours before EPO induction.
In induction experiments, starved cells (1 X IO7 cells/mL) were incubated with 50 nmd/L Na3V04 at 37°C for 15 minutes, exposed to EPO (10 to 50 U/mL) for 30 minutes, collected by microcentrifugation, and lysed in 200 pL of 1% Triton X-100,50 mmol/L NaCl, 30 mmol/L Na4P207, 50 mmol/L NaF, 0.1 mmol/L Na3V04, 10 mmol/L Tris, pH 7.6, 0.5 pg/mL leupeptin, 0.7 pg/mL pepstatin, 50 pg/mL phenymethylsulfonyl fluoride, and 0.1% bovine serum albumin (lysis buffer). In immunoprecipitations, lysates were preexposed to protein A-sepharose (Sigma Chemicals, St Louis, MO) and then incubated with monoclonal antibody (MoAb) 12CA5 (20 pg; Berkeley Antibody Co, Berkeley, CA) for 2 hours at 4°C. Immune complexes then were absorbed using protein A-sepharose (45 minutes at 4°C) and were eluted in sample buffer for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting of immune complexes was performed using antiserum to p85 of P13K33 or to EPO receptor peptides. 34 Detection was by NBT/BICP using alkaline phosphatase-conjugated second antibodies (Promega, Madison, WI).
Alternatively, starved cells were incubated in phosphate-free DMEM (Sigma Chemicals) supplemented with 1% fetal calf serum for 30 minutes and labeled metabolically for 2.5 hours in this medium containing 0.5 mCi/mL [32P]orthophosphate (ICN, Irvine, CA). Incubations with orthovanadate and EPO were performed as described above. 32P-labeled proteins from Triton X-100 lysates were precipitated using MoAb 12CA5, antiphosphotyrosine MoAb PY20 (ICN), or antiserum to p85 (PI3-K) plus protein A-sepharose. 32P-phosphoproteins were eluted as above, and analyzed by SDS-PAGE and autoradiography.
Baculovirus constructs and expression of p85 and EPO receptor forms in SF9 cells. cDNA constructs encoding HER, HER-E374, HER-K256, and HERAB X 2 were subcloned into the baculovirus transfer vector pVL1393 (Invitrogen, San Diego, CA) at Kpn I and Not I sites. These plasmids then were cotransfected into insect SF9 cells35 together with linear, replication-defective baculovirus DNA (Pharmingen, San Diego, CA). Recombinant viruses were collected from transfected cells at 72 hours postinfection and were amplified by repeated infections. Expression levels were assessed by Western blotting using either antiserum to receptor peptides or MoAb 12CA5. The baculovirus vector for expression of p85 was as described previously." In studies of association of p85 with HAItagged EPO receptor forms, SF9 cells were coinfected with cognate baculovirus vectors, collected 45 hours postinfection, lysed, and analyzed by immunoprecipitation (MoAb 12CA5) and Western blotting as described above.
Immunoprecipitations of EPO receptors were performed in FDC-HER cells using MoAb 12CA5 or anti-EPO receptor peptide antibodies as described above. After incubations with protein A-sepharose, gels were washed three times with each of the following buffers: PBS, pH 7.4; 50 mmol/L LiC1, 100 mmol/L Tris-HC1, pH 7.4; 100 mmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L Tris-HC1, pH 7. 
RESULTS
Association ofp85(PI3-K) with thecloned EPO receptor in FDC-HER cells. In a direct approach towards identifying cofactors that may associate with the cloned murine EPO receptor, an epitope-tagged receptor form was constructed and expressed stably in IL-3/GM-CSF-dependent murine myeloid FDC-P I cells. Epitope-tagging was undertaken based on the low efficiency of immune precipitation observed using available antisera. An eight-amino acid epitope tag (YDVPDYAS) derived from hemagglutinin influenza virus was used, and was encoded (together with the secretory signal peptide from human EPO) at the immediate amino terminus ofthe mature receptor (Fig IA) . The corresponding cDNA construct was cloned into a modified pXM expression vector and was transfected stably into FDC-PI cells. Selection in G418 and EPO yielded cell lines with acquired factor-dependency for EPO (FDC-HER cells), thus initially confirming the mitogenic activity of this HA1 epitope-tagged receptor form (HER). In quantitative growth assays, FDC-HER cells were shown to proliferate in response to EPO (at 5 U/mL) at approximately 50% of maximal rates observed for control FDC-PI cells expressing the wild-type EPO receptor (ie, FDC-ER cells) (Fig IB) . This analysis showed that Epo-induced mitogenic signalling via the tagged HER is detectably compromised, yet efficient. Immunoprecipitation of HERS from FDC-HER cell lysates with the cognate MoAb 12CA5 also was efficient. This was shown by Western blotting of immunoprecipitated HERS using antiserum to EPO receptor peptides (Fig IC) . Immunoprecipitation of this epitope-tagged receptor was specific and was inhibited by HA1 competitor peptide. Also, no detectable levels of receptor were observed in samples from control FDC-ER cells.
Using FDC-HER cells, factors in possible direct association with the EPO receptor were next screened initially by labeling FDC-HER-cells metabolically with [32Pj-orthophosphate and immunoprecipitating EPO receptors from Triton X-100 cell lysates. As shown in Fig 2, an Mr 85,000 32P-phosphoprotein was observed to specifically coimmunoprecipitate with HER/MoAb 12CA5 complexes (arrows). This phosphoprotein was not detected in control samples from FDC-ER cells ( lanes I and 2 v 3 and 4) and its immunoprecipitation was inhibited by competitor HA1 peptide (not shown). Notably, the apparent association of this Mr 85,000 phosphoprotein with HERs was constitutive, and was not affected on the exposure of factor-deprived FDC-HER cells ( I O hours of incubation in DMEM, 1% FCS) to EPO (20 U/mL). In contrast, EPO exposure was observed to stimulate the phosphorylation of ppl00 in FDC-HER cells (final two lanes; identical subdivided samples). As mentioned above, thisphosphoprotein(ppl00)previously has been identified by our laboratory as a common cytosolic target for EPO, IL-3, and GM-CSF-induced tyrosine phosphorylation.20.22
Based in part on molecular weight, the possibility that the observed HER-associated Mr 85,000 phosphoprotein might correspond to the p85 regulatory subunit of P13-K was assessed. As a preliminary test, p85(P13-K) was labeled metabolically in FDC-HER cells with [32P]orthophosphate, was immunoprecipitated using specific antiserum, and was observed to comigrate in SDS-PAGE with the above HER-associated phosphoprotein (Fig 2) . Based on this result, HERMoAb 12CA5 immunoprecipitates from FDC-HER cells subsequently were assayed directly for receptor-associated p85 (P13-K) by Western blotting with p85-specific antiserum (Fig 3) . p85 was detected in these immune precipitates and was not detectable in control samples from FDC-ER cells: also, its specific coimmunoprecipitation with the HER was inhibited by HA1 competitor peptide. Consistent with the above 32P-labeling experiments, EPO exposure had no apparent effect on levels of receptor-associated p85. However, EPO was observed to rapidly induce the phosphorylation of phosphatidylinositol as assayed in factor-deprived FDC-ER and FDC-HER cells (Fig 4) . This is shown as a dependence of phosphatidylinositol 32P-phosphate formation on length of exposure of FDC-ER and FDC-HER cells to EPO (20 U/mL). In each cell line, a highly similar timecourse of phosphatidylinositol-phosphate production was observed, further confirming that the efficiency of signalling via HA1 epitope-tagged receptors (FDC-HER cells) is comparable to that of wild-type receptors (FDC-ER cells).
Association ofp85(P13-K) with the EPO receptor at an essential mended box-2 subdomain. Domains of the EPO receptor that mediate its observed association with the p85 subunit of P13-K were delineated by expressing p85 together with HER cytosolic deletion mutants in insect SF9 cells, and assaying for their association by coimmunoprecipitation with MoAb 12CA5. Receptor deletion mutants tested included forms truncated at the carboxy terminus (ie,
-

HER-E374; HER-KZ56) and deleted at consensus box 2 subdomain (HERAB X 2) (Fig 5A) . As assessed by Western blotting, expression levels in SF9 cells (48 hours postinfection) were approximately equivalent for each receptor form (Fig 5B) . Coinfection of SF9 cells with baculovirus vectors encoding these EPO receptor forms and the p85 subunit of PI3-K resulted in the association of p85 with HER-E374, HERAB X 2, and the wild-type HER as shown by coimmunoprecipitation with MoAb 12CA5 and Western blotting of precipitates with p85 antiserum (Fig 6) . In contrast, p85 failed to associate efficiently with the truncated HER-K256 receptor form. Therefore, the site for p85 binding is indicated to be contained within one oftwo possible subdo- (YLEL),40 and therefore is suggested to comprise a site for direct association ofthe EPO receptor with p85. Also, Western blotting of baculovirus-expressed receptor forms (including HER-E374) with the antiphosphotyrosine antibody PY20 indicated that Y343 is phosphorylated in SF9 cells. Alternatively, it is possible that association of p85 with the EPO receptor might occur through a domain of p85 that is distinct from the terminal SH2 domains or may depend on an intermediating accessory factor.
DISCUSSION
Using an active, epitope-tagged form of the murine EPO receptor, the present study directly demonstrates the association of the p85 regulatory subunit of P13-K with this receptor in FDC-HER cells. Moreover, this association is observed to occur in factor-deprived cells: no increases in levels of receptor-associated p85 are observed on exposure to EPO: and no modulation in overall levels of phosphorylation of receptor-associated p85 is apparent. However. EPO is shown to rapidly induce the formation ofphosphatidylinositol '*P-phosphate in FDC-HER and FDC-ER cells. These observations show convincingly that the association of p85 with the EPO receptor in FDC-HER cells is constitutive and raise important questions regarding mechanisms of PI3-K activation and the possible role of PI3-K in EPOstimulated cell proliferation.
With regard to mechanisms for activation of P13-K in FDC-HER cells, by analogy, to P13-K activation in PTKencoding receptor systems (eg, EGF and PDGF recep t~rs).'~.~' these are thought to include ligand-induced binding of p85 via SH2 motifs to phosphotyrosine residues within activated receptors. Subsequently, the pl IO catalytic subunit42 of P13-K then may gain access to membrane phosphatidylinositol s~bstrates.~~ In contrast, in the EPO receptor system, p85 presently is shown to preassemble constitumunoprecipitated from Triton X-1 00 lysates using MoAb 12CA5. p85 that bound to these receptor forms was assayed by coimmunoprecipitation with MoAb 12CA5 and Western blotting of precipitates using specific antiserum to p85. Controls included cells infected only with baculoviruses encoding HER forms ([ -1 lanes v SF9-p85) tively with receptor in the absence of ligand. thus indicating that alternative mechanisms may exist for EPO-induced P13-K activation. Most recently. EPO has been shown to activate JAK2" (a directly associated Janus-type PTK)24 and has been shown previously to stimulate 'the tyrosine phosphorylation of gap120,'7 raf-1.I6 pp100,'5*2G22 ~~1 3 0 . '~ and the EPO receptor per se." Consequently, one possible mechanism for P13-K activation in FDC-HER cells is the direct, induced (tyrosine) phosphorylation of receptor-associated p85 (plIO/PI3-K). Previously, this has been proposed as a possible mechanism for P13-K activation in IL-2 receptor system4' and presently is being assessed in the EPO receptor system. Alternatively. because EPO-induced tyrosine phosphorylation of the EPO receptor is primarily at distal carboxyl-terminal residues," induced receptor phosphorylation also might contribute allosterically to p85/ pl IO/P13-K activation. Consistent with this model is the recent observation that activated p85/P13-K complexes can be retrieved in association with tyrosine phosphorylated forms of the EPO receptor from Ba/F3 cells using biotinylated EPO." However, in this latter study, immunoprecipitation of EPO receptor complexes was not possible using available antisera: therefore, preassembly of receptor with p85 could not be addressed. Interestingly. the issue of ligand-induced versus apparent constitutive assembly of EPO receptor complexes also may extend to a consideration of nonreceptor PTK activation. As mentioned above, the EPO receptor recently has been shown in vitro to associate in the absence of ligand with the cytosolic PTK, JAK2.2' Using the HAI-tagged murine EPO receptor and antiserum to JAK2, we likewise have observed receptor-JAK2 association (ie, coimmunoprecipitation) in FDC-HER cells (T-C.H. and D.M.W. unpublished data). Notably, JAKZ also has been shown to associate with the receptor for growth hormone (GH)?' However, in the GH system, ligand binding apparently is required both for GH receptor-JAK2 association as well as for JAKZ activation. Thus, these observations, together with the present work, underline the likehood that discrete molecular mechanisms and/ or cofactors for P13-K regulation may exist among various growth factor receptor systems.
Using recombinant factors expressed in SF9 cells, a putative EPO receptor cytosolic subdomain for p85 binding (ie, P329-E374) also presently is delineated. Located within this domain, and specifically within an extended box 2 region (which has been shown previously to be essential for EPO induced mitogenesis),'0,'' is a single putative motif for SH2 binding (ie, Y343LVL). Because in essentially all systems defined to date, binding of p85 to growth factor receptor complexes is via amino-and/or carboxyl-terminal p85 SH2 domains, the Y343LVL motif ofthe EPO receptor is considered to comprise a likely site for p85 association. This sequence approximates SH2 binding motifs that occur within the EGF3' and basic FGF receptors,40 for example, with variability observed within third position (V, D, and G, respectively). However, in this context, it is noteworthy that no consensus motifs for SH2 binding occur within either the EPO receptor or, for example, the related 0-receptor for IL-2 that likewise has been shown to bind p85 and to mediate P13-K activation.43 Thus, as further shown by the recent identification of a novel motif for p85 binding in the receptor for hepatocyte growth as yet incompletely defined diversity apparently exists within functional motifs for p85 (SH2) binding. In the EPO receptor system, functional assessment of the YLVL motif as a site for p85 association will derive from the ongoing construction and expression of point-mutated receptor forms in permissive, factor-dependent hematopoietic cell lines.
P13-K is known to catalyze (via a recently cloned pl10 the phosphorylation of the glycosyl moiety of phosphatidylinositol at the D-3 position. Although the action of derived phosphoinositol lipids in signalling is presently undefined, a role for P13-K in proliferative signalling nonetheless is indicated by recent studies in several syst e m~.~~ As a recent and important example, in the PDGF system receptor forms that activate PI3-K yet fail to activate PLC-7 and GAP/ras nonetheless efficiently support liganddependent mitogenesis.47 Based on this observation, it is of significant interest to consider whether distinct receptor domains likewise might be involved in PI3-K versus GAP/ras activation; and whether EPO-activation of P13-K might depend on activation of a nonreceptor PTK (ie, JAK2). The present work establishes an immediately useful model for addressing these specific questions. Ligand-dependent activation of p85(PI3-K) also recently has been shown to be activated in three alternative class I cytokine receptor systems: the IL-7 receptor in pre-B cells48; the IL-4 receptor in FDC-P2 cells49; and the IL-2 p receptor in Baf-BO3 cells.50
In FDC-P2 cells, an association of the IL-4 receptor with p85(PI3-K) was shown. Also, in Baf-BO3 cells, IL-2-dependent activation of P13-K was deficient for an IL-20 receptor deletional mutant lacking a serine-rich domain that is essential for mitogenic signalling, yet apparently dispensable for nonreceptor PTK a~tivation.~' These findings, together with the present work, underline the importance of further defining molecular mechanisms for PI3-K activation via the EPO receptor and related class I cytokine receptor systems, including the possible requirement in this pathway for activated, nonreceptor PTKs (eg, JAK-1 and JAK-2).24 
